Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01015326 · ClinicalTrials.gov registry record
Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 32
- Enrollment target
NCT01015326 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 32 participants.
The verdict
NCT01015326 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
Epidermal Growth Factor Receptor Inhibitors (EGFRI) are associated with skin toxicities. Clinical experience suggests that skin toxicities interfere with health related quality of life (HRQL) and may interfere with treatment adherence. No systematic investigations of EGFRI-associated dermatologic toxicities and impact on HRQL have been reported. No patient-reported outcome measures exist to capture the unique concerns of oncology patients who experience EGFRI-associated dermatologic toxicities. The purpose of this study is to develop a patient-reported outcomes measure to assess dermatologic-related symptoms burden and health-related quality of life among patients receiving an EGFRI, and to develop a grading system for EGFRI-associated dermatologic toxicities.
Interventions
- OTHER Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01015326
The ClinicalTrials.gov registry entry for NCT01015326 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Questionnaire is the first listed.
NCT01015326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01015326 about?
NCT01015326 is a clinical study titled "Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors". Epidermal Growth Factor Receptor Inhibitors (EGFRI) are associated with skin toxicities. Clinical experience suggests that skin toxicities interfere with health related quality of life (HRQL) and may interfere with treatment adherence. No systematic investigations of EGFRI-associated dermatologic to...
What is the current status of trial NCT01015326?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2006-07. Estimated completion is 2009-11.
What interventions are being tested in trial NCT01015326?
The interventions under investigation include: Questionnaire (OTHER).
Who is sponsoring clinical trial NCT01015326?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.